Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02766699 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM
A Phase 1 study, sponsored by Engeneic Pty Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02766699 is a Phase 1 study that has completed, run by Engeneic Pty Limited. The registered enrollment target is 9 participants.
The verdict
NCT02766699, a Phase 1 study, has completed, sponsored by Engeneic Pty Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of the Cerebral EDV study is to determine the safety and tolerability of EGFR(V)-EDV-Dox in order to establish the best dose level to be used in future studies. The study will also examine the body's immune response to EGFR(V)-EDV-Dox and assess if it is effective in the treatment of patients with recurrent glioblastoma multiforme (GBM).
Interventions
- DRUG EGFR(V)-EDV-Dox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2016-10-25 |
| Est. Completion | 2022-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02766699
The ClinicalTrials.gov registry entry for NCT02766699 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Engeneic Pty Limited, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EGFR(V)-EDV-Dox is the first listed.
NCT02766699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02766699 about?
NCT02766699 is a clinical study titled "A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM". The purpose of the Cerebral EDV study is to determine the safety and tolerability of EGFR(V)-EDV-Dox in order to establish the best dose level to be used in future studies. The study will also examine the body's immune response to EGFR(V)-EDV-Dox and assess if it is effective in the treatment of pat...
What is the current status of trial NCT02766699?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2016-10-25. Estimated completion is 2022-03-30.
What interventions are being tested in trial NCT02766699?
The interventions under investigation include: EGFR(V)-EDV-Dox (DRUG).
Who is sponsoring clinical trial NCT02766699?
This trial is sponsored by Engeneic Pty Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.